Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
Abstract
As we continue to battle the COVID-19 pandemic, we must confront the possibility of new pathogenic coronaviruses emerging in humans in the future. With this in mind, Rappazzo et al. isolated antibodies from a survivor of the 2003 severe acute respiratory syndrome coronavirus (SARS-CoV), used yeast display libraries to introduce diversity into these antibodies, and then screened for binding to SARS-CoV-2. One of the affinity-matured progeny strongly neutralized SARS-CoV-2, SARS-CoV, and two SARS-related viruses from bats. In addition, this antibody bound to the receptor-binding domains from a panel of sarbecoviruses, suggesting broader activity, and provided protection against SARS-CoV and SARS-CoV-2 in mouse models.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 19, 2021
- Source ID
- 10.1126/science.abf4830
Entities
People
- Andrew S Herbert
- Bronwyn M Gunn
- C Garrett Rappazzo
- Cecilia M O'Brien
- Chengzi I. Kaku
- Daniel Wrapp
- David Nemazee
- Deli Huang
- Dennis R. Burton
- James C. Geoghegan
- James E Voss
- Jason S. McLellan
- John M Dye
- Jonathan Belk
- Laura M Walker
- Laura M. Deveau
- Linghang Peng
- Linlin Yang
- Lisa E. Gralinski
- Longping V Tse
- Michael B Battles
- Michael E. Brown
- Mrunal Sakharkar
- Ralph S. Baric
- Thomas J. Yockachonis
- Trevor D. Scobey
- Yixuan Hou
Organizations
- Gates Foundation
- Geneva Foundation
- Massachusetts Institute of Technology
- National Institutes of Health
- Scripps Research
- United States Army Medical Research Institute of Infectious Diseases
- University of North Carolina at Chapel Hill
- University of Texas at Austin
- Washington State University